Currently, the interest is directed to further explore changes in tumour microenvironment that can be induced by IFNγ and also to investigate the combination of IFNγ with other types of immunotherapies and especially with anti-PD1 treatment (72). The gene discussed is PDCD1; the disease is neoplasm.